Addressing Under-treatment and Health Equity in Aortic Stenosis and Mitral Regurgitation Using an Integrated EHR Platform

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients with definitive or possible severe AS or MR on echocardiogram. These endpoints will also be examined within and between assigned groups according to race, ethnicity, sex, and geography. The primary question that will be answered: Do automated alerts sent to clinical providers decrease under-treatment of severe aortic stenosis and severe mitral regurgitation? The study will compare the rate of clinical follow-up and aortic valve surgery in a control group (no alerts sent) to a treatment group (alerts sent to an appropriate care provider).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

∙ At least one of the following three options for aortic stenosis and/or the single option for mitral regurgitation are determined from echocardiogram findings:

• AVA or DI (Patients with either Aortic valve area (AVA) or Dimensionless Index (DI) measured in their echo as well as at least one hemodynamic measure above the minimum threshold)

• a. Either: i. Aortic Valve Area ≤ 1.0 cm2 ii. Dimensionless Index ≤ 0.25 b. AND ANY of i. Aortic Mean Gradient ≥ 15 mmHg ii. Aortic Peak Gradient ≥ 30 mmHg iii. Aortic Jet Velocity ≥ 2.75 m/s

• AVA + OTHER (Patients with AVA and at least 1 other echo measurement in their echo above the threshold)

‣ 1.0 cm2 \< Aortic Valve Area ≤ 1.2 cm2

⁃ AND ANY of:

• i. Aortic Mean Gradient ≥ 40 mmHg ii. Aortic Peak Gradient ≥ 64 mmHg iii. Aortic Jet Velocity ≥ 4.0 m/s

• POSSIBLE (Possible Aortic Stenosis but requires human review) a. Aortic Valve Area is NULL OR \>1.2 cm2 b. AND ANY of: i. Aortic Mean Gradient ≥ 40 mmHg ii. Aortic Peak Gradient ≥ 64 mmHg iii. Aortic Jet Velocity ≥ 4.0 m/s OR a. EITHER i. Aortic Valve Area ≤ 1.0 cm2 ii. Dimensionless Index ≤ 0.25 b. AND ALL are: i. Aortic Mean Gradient \< 15 mmHg ii. Aortic Peak Gradient \< 30 mmHg iii. Aortic Peak Velocity \< 2.75 m/s

∙ ALERT Study Clinical Investigation Plan Version 2.1 page 12 of 54

∙ Any patient flagged for POSSIBLE does not result in automatically alerting the provider, instead a notification is sent to the Tempus research team for manual review in conjunction with the site Principal Investigator (PI) and if requested by Tempus or site PI, a Steering Committee member. If clinical confirmation is received for severe aortic stenosis from the site PI, an alert is sent to the provider. 1. Mitral Regurgitation

∙ a. Mention of severe mitral regurgitation or moderate- severe mitral regurgitation

∙ Any patient mentioned with only moderate MR or a lesser severity will be excluded.

Locations
United States
Missouri
Saint Luke's Health System
RECRUITING
Kansas City
Ohio
OhioHealth
NOT_YET_RECRUITING
Columbus
Bon Secours Mercy Health - Lima Market
NOT_YET_RECRUITING
Lima
Oregon
Oregon Health and Science University
NOT_YET_RECRUITING
Portland
Tennessee
Vanderbilt
RECRUITING
Nashville
Virginia
Bon Secours Mercy Health - Richmond Market
RECRUITING
Richmond
Contact Information
Primary
Chris Rogers, BS
chris.rogers@tempus.com
(414) 220-4384
Backup
Loren Wagner, PhD
loren.wagner@tempus.com
(414) 234-0384
Time Frame
Start Date: 2024-08-27
Estimated Completion Date: 2025-12
Participants
Target number of participants: 2626
Treatments
Experimental: Automated alert
Providers that will receive an automated alert sent via the EHR.
No_intervention: Control
Care providers in the control arm will not receive an automated alert.
Sponsors
Leads: Tempus AI
Collaborators: Medtronic

This content was sourced from clinicaltrials.gov